Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Accumulated Expenses of $69.8 million for Q1 2026, up 811.51% year-over-year from $7.7 million in Q1 2025, and down 28.69% quarter-over-quarter from $97.8 million in Q4 2025.
Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Accumulated Expenses for 10 consecutive years, with $69.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 811.51% year-over-year to $69.8 million; the TTM figure through Mar 2026 stood at $69.8 million (up 811.51% YoY), while the FY2025 annual figure was $97.8 million, up 7.44% from the prior year.
- Accumulated Expenses declined to $69.8 million in Q1 2026 per DNLI's latest filing, from $97.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $97.8 million in Q4 2025 and bottomed at $4.8 million in Q3 2024.
- Historically, Accumulated Expenses has averaged $29.3 million across 5 years, with a median of $10.3 million in 2023.
- Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 70.45% — and 2026, when it surged 811.51%.
- Denali Therapeutics' Accumulated Expenses stood at $66.7 million in 2022, then rose by 2.71% to $68.5 million in 2023, then soared by 32.95% to $91.1 million in 2024, then climbed by 7.44% to $97.8 million in 2025, then dropped by 28.69% to $69.8 million in 2026.
- Business Quant data shows DNLI's Accumulated Expenses at $69.8 million in Q1 2026, $97.8 million in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.28 Mn |
| Mar 31, 2026 | 69.78 Mn |
| Dec 31, 2025 | 97.85 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 12.07 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Dec 31, 2024 | 91.07 Mn |
| Sep 30, 2024 | 4.83 Mn |
| Jun 30, 2024 | 6.01 Mn |
| Mar 31, 2024 | 8.05 Mn |
| Dec 31, 2023 | 68.50 Mn |
| Sep 30, 2023 | 16.34 Mn |
| Jun 30, 2023 | 10.26 Mn |
| Mar 31, 2023 | 7.37 Mn |
| Dec 31, 2022 | 66.69 Mn |
| Sep 30, 2022 | 13.25 Mn |
| Jun 30, 2022 | 8.32 Mn |
| Mar 31, 2022 | 5.84 Mn |
| Dec 31, 2021 | 19.01 Mn |
| Sep 30, 2021 | 10.53 Mn |